CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Harvard researchers have found that M. morganii may contribute to depression by producing an inflammatory molecule.

The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Drug is the first and only approved monotherapy for refractory major depressive disorder ... “Treatment-resistant depression can be very complicated, especially for patients who do not respond ...